Trexquant Investment LP Corvus Pharmaceuticals, Inc. Transaction History

Trexquant Investment LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 13, 2019	SELL	$3.29 - $8.94 $41,069 - $111,598	-12,483 Closed	0 $0
Q3 2018 Nov 09, 2018	BUY	$8.58 - $11.4 $107,104 - $142,306	12,483 New	12,483 $107,000
Q1 2018 May 03, 2018	SELL	$7.48 - $11.53 $134,423 - $207,205	-17,971 Closed	0 $0
Q4 2017 Feb 09, 2018	BUY	$9.3 - $16.93 $167,130 - $304,249	17,971	17,971 $186,000

30.4M

1.06M

84.3K

Ticker CRVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,553,500
Market Cap $413M
Description
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...

Get notified when there are updates to the investment portfolio of Trexquant Investment LP, based on Form 13F filings with the SEC.

Stay updated on Trexquant Investment LP with notifications on news.